YES1 gene amplification occurs in some types of cancer and is a key mechanism of resistance to EGFR or HER2 inhibitors, while downregulation of YES1 inhibits cell growth in several malignancies, including colon carcinoma, rhabdomyosarcoma, and basal-like breast cancer [18]. Here, ERBB2 is linked to cancer.